Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe Thursday, March 4, 2021 1:52PM IST (8:22AM GMT)
Updated protocol allows for faster and more convenient administration of Sculptra® with the optional addition of lidocaine to increase patient comfort Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of Sculptra® Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol Galderma today announced a European re-launch of Sculptra ® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.